论文部分内容阅读
目的:研究化疗后止呕药联合侧脑室注射orexin能否改善顺铂诱导的异食癖与食欲减退,进一步探索吡嘧司特联合orexin抗呕吐的机制。方法:1腹腔注射止呕药并侧脑室置管给予orexin,观察大鼠高岭土摄取及摄食改变。2EIA法测量脑脊液中P物质含量。结果:1顺铂中高剂量组高岭土摄入增加、摄食和体重减少,呈量效依赖关系(P<0.05~0.01)。2恩丹西酮早期抑制高岭土摄入(P<0.05)。联合用药后延长该效应且晚期增加摄食(P<0.05)。3阿瑞吡坦晚期抑制高岭土摄入,呈量效依赖关系(P<0.05~0.01),联合用药后第4天,高岭土摄取减少、摄食增加(P<0.05)。4吡嘧司特晚期抑制高岭土摄入,呈量效依赖关系(P<0.05~0.01)。高剂量吡嘧司特晚期增加摄食(P<0.05)。联合用药后第4、5天,高岭土摄入减少,第1、4、5天摄食增加(P<0.05)。5注射顺铂脑脊液中P物质浓度升高(P<0.05)。联合用药能够降低P物质浓度(P<0.05)。结论:联合应用orexin能够延长止呕药作用期并改善顺铂引起的食欲减退。吡嘧司特通过减少P物质的含量,抑制高岭土摄入。
OBJECTIVE: To investigate whether chemotherapy combined with antinomia combined with intracerebroventricular injection of orexin can ameliorate cisplatin-induced pica and loss of appetite, and to further explore the mechanism of combination of porprilizin and orexin against vomiting. Methods: 1 Intraperitoneal injection of antiemetic drugs and lateral ventricular catheterization given orexin, observed changes in rat kaolin intake and feeding. 2EIA method to measure the content of substance P in cerebrospinal fluid. Results: 1 The dose of high dose Cisplatin increased kaolin intake, food intake and weight loss in a dose-dependent manner (P <0.05 ~ 0.01). 2 Ondansetron inhibited early kaolin intake (P <0.05). This effect was prolonged after combination therapy and increased food intake late (P <0.05). 3 Aprepitant inhibited kaolin uptake in the late phase (P <0.05 ~ 0.01). On the 4th day after combination therapy, the uptake of kaolin decreased and food intake increased (P <0.05). 4 pyramizumab late inhibition of kaolin uptake, was dose-dependent (P <0.05 ~ 0.01). High dose of azpirofibrate late increased feeding (P <0.05). On the 4th and 5th day after the combination therapy, the intake of kaolin decreased and the feeding on the 1st, 4th and 5th days increased (P <0.05). 5 injected cisplatin cerebrospinal fluid substance P concentration (P <0.05). Combination therapy can reduce substance P concentration (P <0.05). Conclusion: The combination of orexin can prolong the action period of antinociception and improve the anorexia caused by cisplatin. Pyrazimast inhibits kaolin uptake by reducing substance P content.